HIF-1 (hypoxia-inducible factor 1) is a critical regulator of oxygen homeostasis, playing a key role in various human diseases. HIF-1 consists of HIF-1α and HIF-1β subunits, with HIF-1α expression and activity regulated by oxygen levels. Under hypoxia, HIF-1α is stabilized and translocates to the nucleus, where it binds to hypoxia-response elements to activate the transcription of genes such as VEGF (vascular endothelial growth factor), which is essential for angiogenesis. This process is crucial for tissue perfusion and survival under hypoxic conditions. HIF-1 is involved in several major diseases, including ischemic cardiovascular disorders, cerebral ischemia, retinal ischemia, pulmonary hypertension, and cancer. In ischemic heart disease, HIF-1 activation promotes angiogenesis and helps restore blood flow to ischemic myocardium. In cerebral ischemia, HIF-1 contributes to neuronal survival and neovascularization. In retinal ischemia, HIF-1 regulates VEGF expression, which is critical for preventing blindness in diabetic retinopathy. In pulmonary hypertension, HIF-1 activity is linked to vascular remodeling and right heart failure. In cancer, HIF-1 is overexpressed and promotes tumor growth by inducing angiogenesis, glucose metabolism, and cell survival. Tumor suppressor genes like VHL and p53 regulate HIF-1 activity, while oncogenes such as v-SRC and RAS can enhance HIF-1 expression. HIF-1 also plays a role in pregnancy disorders like preeclampsia and intrauterine growth restriction by regulating trophoblast invasion and placental development. Understanding HIF-1's role in disease pathophysiology is crucial for developing therapeutic strategies targeting HIF-1 activity. These strategies include modulating HIF-1 expression or activity to promote angiogenesis in ischemic conditions or inhibit tumor growth in cancer. Research into HIF-1's mechanisms and its interactions with other signaling pathways is ongoing, with the potential for new therapeutic approaches in the future.HIF-1 (hypoxia-inducible factor 1) is a critical regulator of oxygen homeostasis, playing a key role in various human diseases. HIF-1 consists of HIF-1α and HIF-1β subunits, with HIF-1α expression and activity regulated by oxygen levels. Under hypoxia, HIF-1α is stabilized and translocates to the nucleus, where it binds to hypoxia-response elements to activate the transcription of genes such as VEGF (vascular endothelial growth factor), which is essential for angiogenesis. This process is crucial for tissue perfusion and survival under hypoxic conditions. HIF-1 is involved in several major diseases, including ischemic cardiovascular disorders, cerebral ischemia, retinal ischemia, pulmonary hypertension, and cancer. In ischemic heart disease, HIF-1 activation promotes angiogenesis and helps restore blood flow to ischemic myocardium. In cerebral ischemia, HIF-1 contributes to neuronal survival and neovascularization. In retinal ischemia, HIF-1 regulates VEGF expression, which is critical for preventing blindness in diabetic retinopathy. In pulmonary hypertension, HIF-1 activity is linked to vascular remodeling and right heart failure. In cancer, HIF-1 is overexpressed and promotes tumor growth by inducing angiogenesis, glucose metabolism, and cell survival. Tumor suppressor genes like VHL and p53 regulate HIF-1 activity, while oncogenes such as v-SRC and RAS can enhance HIF-1 expression. HIF-1 also plays a role in pregnancy disorders like preeclampsia and intrauterine growth restriction by regulating trophoblast invasion and placental development. Understanding HIF-1's role in disease pathophysiology is crucial for developing therapeutic strategies targeting HIF-1 activity. These strategies include modulating HIF-1 expression or activity to promote angiogenesis in ischemic conditions or inhibit tumor growth in cancer. Research into HIF-1's mechanisms and its interactions with other signaling pathways is ongoing, with the potential for new therapeutic approaches in the future.